363 related articles for article (PubMed ID: 24675670)
21. Analysis of Risk Alleles and Complement Activation Levels in Familial and Non-Familial Age-Related Macular Degeneration.
Saksens NT; Lechanteur YT; Verbakel SK; Groenewoud JM; Daha MR; Schick T; Fauser S; Boon CJ; Hoyng CB; den Hollander AI
PLoS One; 2016; 11(6):e0144367. PubMed ID: 27258093
[TBL] [Abstract][Full Text] [Related]
22. Clinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degeneration.
Hageman GS; Gehrs K; Lejnine S; Bansal AT; Deangelis MM; Guymer RH; Baird PN; Allikmets R; Deciu C; Oeth P; Perlee LT
Hum Genomics; 2011 Jul; 5(5):420-40. PubMed ID: 21807600
[TBL] [Abstract][Full Text] [Related]
23. Growth of geographic atrophy on fundus autofluorescence and polymorphisms of CFH, CFB, C3, FHR1-3, and ARMS2 in age-related macular degeneration.
Caire J; Recalde S; Velazquez-Villoria A; Garcia-Garcia L; Reiter N; Anter J; Fernandez-Robredo P; Alfredo García-Layana ;
JAMA Ophthalmol; 2014 May; 132(5):528-34. PubMed ID: 24557084
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss.
Francis PJ; Hamon SC; Ott J; Weleber RG; Klein ML
J Med Genet; 2009 May; 46(5):300-7. PubMed ID: 19015224
[TBL] [Abstract][Full Text] [Related]
25. Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Maguire MG; Ying GS; Jaffe GJ; Toth CA; Daniel E; Grunwald J; Martin DF; Hagstrom SA;
JAMA Ophthalmol; 2016 Jun; 134(6):674-81. PubMed ID: 27099955
[TBL] [Abstract][Full Text] [Related]
26. Association of specific genetic polymorphisms with age-related macular degeneration in a northern Chinese population.
Zhuang W; Li H; Liu Y; Zhao J; Ha S; Xiang W; Bai X; Li Z; Han Y; Sheng X
Ophthalmic Genet; 2014 Sep; 35(3):156-61. PubMed ID: 24865190
[TBL] [Abstract][Full Text] [Related]
27. Complement Activation Levels Are Related to Disease Stage in AMD.
Heesterbeek TJ; Lechanteur YTE; Lorés-Motta L; Schick T; Daha MR; Altay L; Liakopoulos S; Smailhodzic D; den Hollander AI; Hoyng CB; de Jong EK; Klevering BJ
Invest Ophthalmol Vis Sci; 2020 Mar; 61(3):18. PubMed ID: 32176267
[TBL] [Abstract][Full Text] [Related]
28. Variations in five genes and the severity of age-related macular degeneration: results from the Muenster aging and retina study.
Farwick A; Dasch B; Weber BH; Pauleikhoff D; Stoll M; Hense HW
Eye (Lond); 2009 Dec; 23(12):2238-44. PubMed ID: 19169232
[TBL] [Abstract][Full Text] [Related]
29. Joint association of complement component 3 and CC-cytokine ligand2 (CCL2) or complement component 3 and CFH polymorphisms in age-related macular degeneration.
Bonyadi M; Jabbarpoor Bonyadi MH; Yaseri M; Mohammadian T; Fotouhi N; Javadzadeh A; Soheilian M
Ophthalmic Genet; 2017; 38(4):365-370. PubMed ID: 28095095
[TBL] [Abstract][Full Text] [Related]
30. CRISPR Manipulation of Age-Related Macular Degeneration Haplotypes in the Complement System: Potential Future Therapeutic Applications/Avenues.
Salman A; McClements ME; MacLaren RE
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338978
[TBL] [Abstract][Full Text] [Related]
31. A Novel Complotype Combination Associates with Age-Related Macular Degeneration and High Complement Activation Levels in vivo.
Paun CC; Lechanteur YTE; Groenewoud JMM; Altay L; Schick T; Daha MR; Fauser S; Hoyng CB; den Hollander AI; de Jong EK
Sci Rep; 2016 May; 6():26568. PubMed ID: 27241480
[TBL] [Abstract][Full Text] [Related]
32. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables.
Seddon JM; Reynolds R; Maller J; Fagerness JA; Daly MJ; Rosner B
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2044-53. PubMed ID: 19117936
[TBL] [Abstract][Full Text] [Related]
33. Age-related macular degeneration-susceptibility single nucleotide polymorphisms in a han chinese control population.
Hu J; Yuan Y; Shen L; Zhang J; Hu N; Guan H
Ophthalmic Epidemiol; 2011 Jun; 18(3):137-42. PubMed ID: 21609242
[TBL] [Abstract][Full Text] [Related]
34. Low-frequency coding variants in CETP and CFB are associated with susceptibility of exudative age-related macular degeneration in the Japanese population.
Momozawa Y; Akiyama M; Kamatani Y; Arakawa S; Yasuda M; Yoshida S; Oshima Y; Mori R; Tanaka K; Mori K; Inoue S; Terasaki H; Yasuma T; Honda S; Miki A; Inoue M; Fujisawa K; Takahashi K; Yasukawa T; Yanagi Y; Kadonosono K; Sonoda KH; Ishibashi T; Takahashi A; Kubo M
Hum Mol Genet; 2016 Nov; 25(22):5027-5034. PubMed ID: 28173125
[TBL] [Abstract][Full Text] [Related]
35. The association between macular pigment optical density and CFH, ARMS2, C2/BF, and C3 genotype.
Loane E; Nolan JM; McKay GJ; Beatty S
Exp Eye Res; 2011 Nov; 93(5):592-8. PubMed ID: 21816153
[TBL] [Abstract][Full Text] [Related]
36. Coding and noncoding variants in the CFH gene and cigarette smoking influence the risk of age-related macular degeneration in a Japanese population.
Mori K; Gehlbach PL; Kabasawa S; Kawasaki I; Oosaki M; Iizuka H; Katayama S; Awata T; Yoneya S
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5315-9. PubMed ID: 17962488
[TBL] [Abstract][Full Text] [Related]
37. Zinc supplementation inhibits complement activation in age-related macular degeneration.
Smailhodzic D; van Asten F; Blom AM; Mohlin FC; den Hollander AI; van de Ven JP; van Huet RA; Groenewoud JM; Tian Y; Berendschot TT; Lechanteur YT; Fauser S; de Bruijn C; Daha MR; van der Wilt GJ; Hoyng CB; Klevering BJ
PLoS One; 2014; 9(11):e112682. PubMed ID: 25393287
[TBL] [Abstract][Full Text] [Related]
38. Genetic control of the alternative pathway of complement in humans and age-related macular degeneration.
Hecker LA; Edwards AO; Ryu E; Tosakulwong N; Baratz KH; Brown WL; Charbel Issa P; Scholl HP; Pollok-Kopp B; Schmid-Kubista KE; Bailey KR; Oppermann M
Hum Mol Genet; 2010 Jan; 19(1):209-15. PubMed ID: 19825847
[TBL] [Abstract][Full Text] [Related]
39. Genetic Variants and Systemic Complement Activation Levels Are Associated With Serum Lipoprotein Levels in Age-Related Macular Degeneration.
Paun CC; Ersoy L; Schick T; Groenewoud JM; Lechanteur YT; Fauser S; Hoyng CB; de Jong EK; den Hollander AI
Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):7766-73. PubMed ID: 26641553
[TBL] [Abstract][Full Text] [Related]
40. Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration.
Spencer KL; Hauser MA; Olson LM; Schmidt S; Scott WK; Gallins P; Agarwal A; Postel EA; Pericak-Vance MA; Haines JL
Hum Mol Genet; 2007 Aug; 16(16):1986-92. PubMed ID: 17576744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
